00:30 , Jan 19, 2019 |  BC Extra  |  Company News

Celgene bolsters immuno-metabolism, immune cell toolbox with Kyn, Obsidian deals

Partnerships with Boston area biotechs Kyn Therapeutics Inc. and Obsidian Therapeutics Inc. announced late this week by Celgene Corp. (NASDAQ:CELG) indicate the big biotech is continuing to build its immuno-metabolism and immune cell therapy toolboxes...
13:42 , Jan 3, 2019 |  BC Innovations  |  Distillery Therapeutics

Transplant

INDICATION: Organ transplant rejection Mouse studies suggest inhibiting CXCL13, CD40L and ICOSLG, which play roles in B cell maturation and activation, could help treat antibody-mediated lung transplant rejection. In a mouse model of antibody-mediated lung...
04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
19:44 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Biogen, UCB report Phase IIb miss for lupus candidate dapirolizumab

Biogen Inc. (NASDAQ:BIIB) and UCB S.A. (Euronext:UCB) reported top-line data showing dapirolizumab pegol missed the primary endpoint in a Phase IIb trial to treat moderate to severe active systemic lupus erythematosus (SLE) in patients receiving...
18:27 , Oct 19, 2018 |  BC Week In Review  |  Company News

Roche culls pipeline, cuts include in-licensed, acquired programs

Roche (SIX:ROG; OTCQX:RHHBY) announced in its 3Q18 earnings it discontinued development of five new molecular entities, including Phase II rheumatoid arthritis candidate RG6125 (SDP051), plus two programs in development for follow-on indications. The pharma lost...
21:29 , Oct 17, 2018 |  BC Extra  |  Company News

Roche culls pipeline, cuts include in-licensed, acquired programs

Roche (SIX:ROG; OTCQX:RHHBY) announced in its 3Q18 earnings it discontinued development of five new molecular entities, including Phase II rheumatoid arthritis candidate RG6125 (SDP051), plus two programs in development for follow-on indications. The pharma lost...
18:46 , Sep 7, 2018 |  BioCentury  |  Emerging Company Profile

Leveraging cross-linking

Lyvgen Biopharma Co. Ltd. is using its xLinkAb platform to develop mAbs that agonize T cell or dendritic cell co-stimulatory receptors with better safety and selectivity for tumors than competing mAbs. According to founder and...
06:15 , Aug 10, 2018 |  BC Week In Review  |  Financial News

Apexigen announces $73M in series B, C rounds

Immuno-oncology company Apexigen Inc. (San Carlos, Calif.) raised a total of $73 million on Aug. 8 in its series B and C rounds. The company closed its series B round with $15 million led by...
17:49 , Aug 8, 2018 |  BC Extra  |  Financial News

Apexigen announces $73M in series B, C rounds

Immuno-oncology company Apexigen Inc. (San Carlos, Calif.) raised a total of $73 million in its series B and C rounds. The company closed its series B round with $15 million led by Decheng Capital, while...
23:38 , Jul 24, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Binding assays; cellular assays A screening method using non-coding SNPs from genome-wide association studies (GWAS) could help identify new drug targets. The method involves five steps: creating double-stranded 31-base pair DNA constructs with each...